Licence Variation: Spironolactone for acne in women

  • NHS England

F14: Notice for changes or additional information

Notice reference: 2024/S 000-020184

Published 2 July 2024, 5:16pm



Section one: Contracting authority/entity

one.1) Name and addresses

NHS England

1st Floor, Quarry House, Quarry Hill

Leeds

LS2 7UE

Contact

Leigh Parker

Email

england.commercialqueries@nhs.net

Country

United Kingdom

NUTS code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

https://www.england.nhs.uk//

Buyer's address

https://www.england.nhs.uk//


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Licence Variation: Spironolactone for acne in women

Reference number

C290475

two.1.2) Main CPV code

  • 85100000 - Health services

two.1.3) Type of contract

Services

two.1.4) Short description

NHS England requires a supplier to apply for a major (type II) MHRA Marketing Authorisation variation for spironolactone. The variation is to add a new indication to the current licence (marketing authorisation) for treating acne in women. The Successful Supplier would need to prepare a dossier for the MHRA including a Risk Management Plan, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data.

To register an interest in responding to this opportunity and obtain a copy of the tender documents please go to: http://health.atamis.co.uk. All communications and Request for Information submissions will be conducted via Atamis. The portal can be accessed at any time of the day and it is free to register.


Section six. Complementary information

six.6) Original notice reference

Notice number: 2024/S 000-018965


Section seven. Changes

seven.1.2) Text to be corrected in the original notice

Section number

II.2.7.4

Instead of
Date

30 June 2026

Read
Date

30 September 2026